Year: 2026
Type: article
Study design: Observational Study
Abstract: Currently there is no established prognostic scoring system for patients with chronic myeloid leukemia (CML) in blast phase (BP). This study aimed to identify prognostic factors of CML-BP in a large cohort of prospectively and retrospectively collected patients and to develop a readily available prognostic scoring system at the onset of BP to enable future comparison between different trials and series. The analyses were based on 275 patients from thirteen countries, collected within the European LeukemiaNet Blast Phase Registry with a median observation time of 45 months and a median OS of 18.9 months. A Cox proportional hazards model for overall survival (OS) was employed, missing values were imputed. The study identified six independent prognostic factors: blast percentage, platelet count, age (all at onset of CML-BP), immunophenotype of BP, extramedullary disease, and previous history of CML. The low-risk group, encompassing 14% of patients, had a median OS of 97 months, the intermediate-risk group (59% of patients) of 22 months, and the high-risk group (27% of patients) of 9 months. Cross-validation demonstrated a good performance of the score, although external validation is strongly recommended. Despite the inherent limitations of registry data, the findings offer robust insights into prognostic factors for CML-BP.
Source: Leukemia
Authors: Michael Lauseker, Tomasz Sacha, Hana Klamova, Julia Yakoleva, Elza Lomaia, Dragana Milojkovic, Christian Fabisch, Franck E. Nicolini, Ulla Olsson-Stromberg, Daniela Zackova, Krzysztof Lewandowski, Philipp Ernst, Fausto Castagnetti, Klaus Hirschbühl, Irena Zupan, Astghik Voskanyan, Aleksandra Gołos, Jochen J. Frietsch, Justyna Gil, Edgar Faber, Stefan W. Krause, Anne Parry, Susanne Saussele, Sonja Heibl, Georg-Nikolaus Franke, Luis Felipe Casado, Edyta Paczkowska, Holger Hebart, Matthias Eder, Peter Anhut, Karolin Trautmann-Grill, Elzbieta Szczepanek, Thomas Südhoff, Elzbieta Patkowska, Alexander Kiani, Thomas Ernst, Jane Apperley, Jiri Mayer, Andreas Hochhaus, Markus Pfirrmann, Annamaria Brioli
Institutions: Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität München, Jagiellonian University, Institute of Haematology and Blood Transfusion, Federal Almazov North-West Medical Research Centre, Hammersmith Hospital, Jena University Hospital, Inserm, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Uppsala University Hospital, Masaryk University, University Hospital Brno, Poznan University of Medical Sciences, Istituto di Ematologia di Bologna, University of Bologna, University of Augsburg, University of Ljubljana, Ljubljana University Medical Centre, Copernicus Memorial Hospital, Universitätsklinikum Würzburg, University Hospital Olomouc, Palacký University Olomouc, Universitätsklinikum Erlangen, Centre Hospitalier Annecy Genevois, Heidelberg University, Medizinische Fakultät Mannheim, Klinikum Wels-Grieskirchen, University Hospital Leipzig, Leipzig University, Complejo Hospitalario Universitario de Toledo, Hospital Universitario de Toledo, Pomeranian Medical University, Medizinische Hochschule Hannover, University Hospital Carl Gustav Carus, Technische Universität Dresden, Klinikum Passau, Instytut Hematologii i Transfuzjologi, Bayreuth Medical Center, Comprehensive Cancer Center Erlangen, Imperial College London, Universitätsmedizin Greifswald, Universität Greifswald
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
Funder: Universitätsklinikum Jena
OpenAlex ID: W7130513158